Altre lingue Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Azioni

688180

CNE1000041Z1

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 03/06/2024			Variaz. 5gg	Var. 1 gen.
28,09 ^CNY	+4,62%		+0,04%	-32,85%

29/04	Shanghai Junshi Biosciences Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
25/04	Shanghai Junshi Biosciences riceve l'approvazione di Hong Kong per il farmaco antitumorale toripalimab	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03
Junshi Bio's 2023 Loss Widens, Misses Estimates	26/02
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Junshi Biosciences Proposes Share Buyback	02/02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	01/02
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	01/02
Shanghai Junshi Biosciences to Narrow Losses	31/01
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	31/01
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	30/01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer	12/01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of General Manager	12/01
Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board	12/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Azioni

688180

CNE1000041Z1

Altre lingue

Filtri